There is no evidence that triple-negative breast cancer affects the endocrine system, but there is a relationship between breast cancer and endocrine disruption. The mammary gland is the target organ for a variety of endocrine hormones, of which estrone and estradiol are directly related to the development of breast cancer. Early age at menarche, late age at menopause, infertility and late age at first childbearing, short breastfeeding time, and estrogen replacement therapy after menopause can increase or prolong estrogen exposure in the body, which is closely related to the development of breast cancer. Triple-negative breast cancer refers to breast cancer patients who are negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Triple-negative breast cancer cannot be treated with endocrine therapy and targeted drugs, but only chemotherapy, which has poorer healing, should be treated in regular hospitals, and early detection and treatment can prolong the survival period.